Fear, Elizabeth J., Aneurin J. Kennerley, Peter J. Rayner, Philip Norcott, Soumya S. Roy, and Simon B. Duckett. “SABRE Hyperpolarized Anticancer Agents for Use in 1H MRI.” Magnetic Resonance in Medicine 88, no. 1 (2022): 11–27.
https://doi.org/10.1002/mrm.29166.
Purpose Enabling drug tracking (distribution/specific pathways) with magnetic resonance spectroscopy requires manipulation (via hyperpolarization) of spin state populations and targets with sufficiently long magnetic lifetimes to give the largest possible window of observation. Here, we demonstrate how the proton resonances of a group of thienopyridazines (with known anticancer properties), can be amplified using the para-hydrogen (p-H2) based signal amplification by reversible exchange (SABRE) hyperpolarization technique. Methods Thienopyridazine isomers, including a 2H version, were synthesized in house. Iridium-based catalysts dissolved in a methanol-d4 solvent facilitated polarization transfer from p-H2 gas to the target thienopyridazines. Subsequent SABRE 1H responses of hyperpolarized thienopyridazines were completed (400 MHz NMR). Pseudo-singlet state approaches were deployed to extend magnetic state lifetimes. Proof of principle spectral-spatial images were acquired across a range of field strengths (7T-9.4T MRI). Results 1H-NMR signal enhancements of −10,130-fold at 9.4T ( 33% polarization) were achieved on thieno[2,3-d]pyridazine (T[2,3-d]P), using SABRE under optimal mixing/field transfer conditions. 1H T1 lifetimes for the thienopyridazines were 18-50 s. Long-lived state approaches extended the magnetic lifetime of target proton sites in T[2,3-d]P from an average of 25-40 seconds. Enhanced in vitro imaging (spatial and chemical shift based) of target T[2,3-d]P was demonstrated. Conclusion Here, we demonstrate the power of SABRE to deliver a fast and cost-effective route to hyperpolarization of important chemical motifs of anticancer agents. The SABRE approach outlined here lays the foundations for realizing continuous flow, hyperpolarized tracking of drug delivery/pathways.